keyword
MENU ▼
Read by QxMD icon Read
search

Brain metastases

keyword
https://www.readbyqxmd.com/read/29456865/a-real-world-example-of-coverage-with-evidence-development-in-australia-ipilimumab-for-the-treatment-of-metastatic-melanoma
#1
Hansoo Kim, Samantha Comey, Karl Hausler, Greg Cook
Background: Australian Government subsidisation of ipilimumab for the treatment of patients with metastatic melanoma was conditional on the sponsor entering a 'managed entry scheme' to assess the 2-year overall survival rate in metastatic melanoma patients who received ipilimumab in the first year of Pharmaceutical Benefits Scheme listing. Methods: All unresectable stage IIIc / IV metastatic melanoma patients treated with at least one dose of ipilimumab therapy in Australia from the PBS listing date to a time point 12 months later (i...
2018: Journal of Pharmaceutical Policy and Practice
https://www.readbyqxmd.com/read/29455079/automatic-detection-and-segmentation-of-brain-metastases-on-multimodal-mr-images-with-a-deep-convolutional-neural-network
#2
Odelin Charron, Alex Lallement, Delphine Jarnet, Vincent Noblet, Jean-Baptiste Clavier, Philippe Meyer
Stereotactic treatments are today the reference techniques for the irradiation of brain metastases in radiotherapy. The dose per fraction is very high, and delivered in small volumes (diameter <1 cm). As part of these treatments, effective detection and precise segmentation of lesions are imperative. Many methods based on deep-learning approaches have been developed for the automatic segmentation of gliomas, but very little for that of brain metastases. We adapted an existing 3D convolutional neural network (DeepMedic) to detect and segment brain metastases on MRI...
February 9, 2018: Computers in Biology and Medicine
https://www.readbyqxmd.com/read/29454155/immune-checkpoint-inhibitors-in-non-small-cell-lung-cancer-nsclc-approaches-on-special-subgroups-and-unresolved-burning-questions
#3
REVIEW
J Remon, N Vilariño, N Reguart
Immune checkpoint inhibitors (ICIs) have been incorporated in the treatment strategy of advanced non-small cell lung cancer (NSCLC). Beyond the already approved indications in first- and second-line setting of advanced NSCLC, new data has recently emerged demonstrating its efficacy in locally advanced disease as maintenance after chemo-radiotherapy and currently several trials are also exploring its efficacy in earlier stages of the disease to evaluate whether these results could be extrapolated to the adjuvant setting...
February 8, 2018: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29454130/abscess-within-a-glioblastoma-mimicking-a-matryoshka-doll
#4
Kislay Kishore, Manish Beniwal, Shilpa Rao, K V L N Rao, Vikas Vazhayil, Dwarkanath Srinivas, Sampath Somanna
BACKGROUND: Abscess co-existing within a brain tumor is a rare entity. Case reports in literature primarily consist of sellar pathology and parenchymal lesions including meningioma, glioma, and metastases. We report a case of glioblastoma with an intra-tumoral abscess in a middle-aged lady with no prior invasive procedure or systemic focus of infection. CASE DESCRIPTION: A 45-year old lady presented with new onset generalized seizures and rapidly progressive left hemiparesis...
February 14, 2018: World Neurosurgery
https://www.readbyqxmd.com/read/29453679/the-impact-of-timing-of-immunotherapy-with-cranial-irradiation-in-melanoma-patients-with-brain-metastases-intracranial-progression-survival-and-toxicity
#5
Rifaquat Rahman, Alfonso Cortes, Andrzej Niemierko, Kevin S Oh, Keith T Flaherty, Donald P Lawrence, Ryan J Sullivan, Helen A Shih
Immunotherapy (IT) is increasingly incorporated in the management of metastatic melanoma patients with brain metastases, but the impact of timing of IT with stereotactic radiosurgery (SRS) remains unclear. The aim of this study was to determine the temporal significance of IT in melanoma patients treated with cranial radiation therapy (RT) with respect to patterns of intracranial progression, overall survival (OS), and toxicity. We retrospectively reviewed consecutive melanoma patients with brain metastases undergoing cranial RT and IT between 2008 and 2015...
February 16, 2018: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/29453166/skull-metastasis-revealing-a-renal-tumor-a-case-report-and-review-of-the-literature
#6
Mohamed Badri, Ghassen Gader, Kamel Bahri, Ihsen Zammel
BACKGROUND: Renal cell carcinomas represent 85% of malignant renal tumors. Typically, the tumor remains asymptomatic a long time before the appearance of urologic clinical signs. In some cases, metastasis can precede the manifestations of the primary tumor. Different sites are potential metastatic localizations for renal tumors, including skull metastases who represent a very rare location. CASE DESCRIPTION: We report the case of a 65-year-old man presented after the appearance of a skull mass...
February 10, 2018: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/29452865/stereotactic-radiosurgery-for-multiple-brain-metastases-results-of-multicenter-benchmark-planning-studies
#7
David J Eaton, Jonathan Lee, Ian Paddick
PURPOSE: Stereotactic radiosurgery is indicated for treatment of multiple brain metastases. Various treatment platforms are available, but most comparisons are limited to single-center studies. As part of a national commissioning program, benchmark planning cases were completed by 21 clinical centers, providing a unique dataset of current practice across a large number of providers and equipment platforms. METHODS AND MATERIALS: Two brain metastases cases were provided, with images and structures predrawn, involving 3 and 7 lesions...
December 30, 2017: Practical Radiation Oncology
https://www.readbyqxmd.com/read/29450203/real-life-experience-of-ceritinib-in-crizotinib-pretreated-alk-advanced-non-small-cell-lung-cancer-patients
#8
Jacques Cadranel, Alexis B Cortot, Hervé Lena, Bertrand Mennecier, Pascal Do, Eric Dansin, Julien Mazieres, Christos Chouaid, Maurice Perol, Fabrice Barlesi, Gilles Robinet, Sylvie Friard, Luc Thiberville, Clarisse Audigier-Valette, Alain Vergnenegre, Virginie Westeel, Khemaies Slimane, Alexandru Buturuga, Denis Moro-Sibilot, Benjamin Besse
Here we report our experience of ceritinib in crizotinib-pretreated patients with anaplastic lymphoma kinase ( ALK ) positive ( ALK + ) non-small cell lung cancer (NSCLC) in a French temporary authorisation for use (TAU) study. The French TAU study included crizotinib-pretreated patients with advanced ALK + or ROS proto-oncogene 1 positive ( ROS1 + ) tumours. Patients received oral ceritinib (750 mg·day -1 as a starting dose) and best tumour response (as evaluated by the investigator) and safety were reported every 3 months...
January 2018: ERJ Open Research
https://www.readbyqxmd.com/read/29449898/targeted-therapy-of-brain-metastases-latest-evidence-and-clinical-implications
#9
REVIEW
Rodica Di Lorenzo, Manmeet S Ahluwalia
Brain metastases (BM) occur in 20-40% of patients with cancer and 60-75% of patients with BM become symptomatic. Due to an aging population and advances in the treatment of primary cancers, patients are living longer and are more likely to experience complications from BM. The diagnosis of BM drastically worsens long-term survival rates, with multiple metastases being a poor prognostic factor. Until recently, the mainstay of treatment consisted of stereotactic radiosurgery (SRS), surgical resection, whole brain radiation therapy (WBRT), or a combination of these modalities...
December 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/29449515/-therapeutic-effects-of-low-dose-bevacizumab-for-the-treatment-of-recurrent-brain-metastases
#10
Etsuko Hattori, Akinori Miyakoshi, Kohichi Go, Toshiharu Aotake, Yoshiyuki Kawakami, Masato Sakamoto, Takeshi Kawauchi, Yuuki Oichi, Noritaka Sano, Makoto Hayase, Makoto Ohta, Yuki Hirose, Hiroki Toda
OBJECTIVE: Molecularly targeted therapy has been adopted to treat a number of cancers. Bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor, is a representative agent used in molecularly targeted therapeutic regimens. However, the therapeutic effect of bevacizumab for the treatment of brain metastases remains unknown. We report the clinical effects of low dose bevacizumab(≤2.5mg/kg/week)to treat recurrent brain metastases. METHODS: We retrospectively analyzed patients with brain metastases who had been treated with bevacizumab between 2012 and 2016 at our institution...
February 2018: No Shinkei Geka. Neurological Surgery
https://www.readbyqxmd.com/read/29445498/widespread-finger-skin-metastases-of-melanoma
#11
Faruk Tas, Kayhan Erturk
Metastatic melanoma is a fatal disease with a rapid systemic dissemination. Almost every organ might be affected, but lungs, liver, bone, brain, and skin are the most frequently involved sites. Intravascular microtumoral embolism is believed to account for the distant cutaneous metastases that might be the first manifestation of disease progression in most of the cases.
February 2018: Clinical Case Reports
https://www.readbyqxmd.com/read/29441722/the-growing-importance-of-lesion-volume-as-a-prognostic-factor-in-patients-with-multiple-brain-metastases-treated-with-stereotactic-radiosurgery
#12
David M Routman, Shelly X Bian, Kevin Diao, Jonathan L Liu, Cheng Yu, Jason Ye, Gabriel Zada, Eric L Chang
Stereotactic Radiosurgery (SRS) is considered standard of care for patients with 1-3 brain metastases (BM). Recent observational studies have shown equivalent OS in patients with 5+ BM compared to those with 2-4, suggesting SRS alone may be appropriate in these patients. We aim to review outcomes of patients treated with SRS with 2-4 versus 5+ BM. This analysis included consecutive patients from 1994 to 2015 treated with SRS. Of 1017 patients, we excluded patients with a single BM and patients without adequate survival data, resulting in 391 patients...
February 14, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29437873/brain-distribution-of-a-novel-mek-inhibitor-e6201-implications-in-the-treatment-of-melanoma-brain-metastases
#13
Gautham Gampa, Minjee Kim, Nicholas Cook-Rostie, Janice Laramy, Jann N Sarkaria, Linda Paradiso, Louis DePalatis, William F Elmquist
Clinically meaningful efficacy in the treatment of brain tumors, including melanoma brain metastases (MBM), requires selection of a potent inhibitor against a suitable target, and adequate drug distribution to target sites in the brain. Deregulated constitutive signaling of mitogen-activated protein kinase (MAPK) pathway has been frequently observed in melanoma, and MEK has been identified to be an important target. E6201 is a potent synthetic small molecule MEK inhibitor. The purpose of this study was to evaluate brain distribution of E6201, and examine the impact of active efflux transport at the BBB on the CNS exposure of E6201...
February 2, 2018: Drug Metabolism and Disposition: the Biological Fate of Chemicals
https://www.readbyqxmd.com/read/29437794/drug-resistance-in-her2-positive-breast-cancer-brain-metastases-blame-the-barrier-or-the-brain
#14
Sheheryar Kabraji, Jing Ni, Nancy Lin, Shaozhen Xie, Eric P Winer, Jean J Zhao
The brain is the most common site of first metastasis for patients with HER2-positive breast cancer treated with HER2-targeting drugs. However, the development of effective therapies for breast cancer brain metastases (BCBMs) is limited by an incomplete understanding of the mechanisms governing drug sensitivity in the central nervous system. Pharmacodynamic data from patients and in vivo models suggest that inadequate drug penetration across the 'blood-tumor' barrier is not the whole story. Using HER2-positive breast cancer brain metastases as a case study, we highlight recent data from orthotopic brain metastasis models that implicates brain-specific drug resistance mechanisms in BCBMs and suggests a translational research paradigm to guide drug development for treatment of BCBMs...
February 6, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29437006/enteral-administration-of-tkis-report-of-a-response-to-ceritinib-in-an-alk-positive-nsclc-patient-and-literature-review
#15
Francesco Facchinetti, Paola Bordi, Paola Bini, Livia Bidin, Roberta Camisa, Marcello Tiseo
INTRODUCTION: Several reports attest the feasibility and the favorable outcomes of kinase inhibitors administration through feeding tubes or percutaneous endoscopic gastrostomies (PEG), mainly in non-small cell lung cancer (NSCLC) patients exposed to first-generation compounds. Here we present the case of an ALK-positive NSCLC patient who achieved cerebral and extra-cranial disease response with ceritinib (a novel ALK inhibitor) administered through a nasogastric tube (NGT). We moreover provide a review gathering clinical successes obtained with targeted agents intake through NGT or PEG...
February 12, 2018: Current Drug Targets
https://www.readbyqxmd.com/read/29436722/the-prognosis-of-different-distant-metastases-pattern-in-prostate-cancer-a-population-based-retrospective-study
#16
Jiafeng Shou, Qi Zhang, Shuai Wang, Dahong Zhang
BACKGROUND: The present of metastases is a poor prognostic factor in prostate cancer, but the prognostic impact of different distant metastases pattern is unclear. The aim of this study is to investigate the impact of different distant metastases pattern on the survival of patients with stage IV prostate cancer. METHODS: Data queried for this study include prostate cancer (2010-2014) from the Surveillance, Epidemiology, and End Results (SEER) program. Metastatic distribution information was provided for bone, brain, liver and lung...
February 13, 2018: Prostate
https://www.readbyqxmd.com/read/29435193/targeted-drugs-for-systemic-therapy-of-lung-cancer-with-brain-metastases
#17
REVIEW
Ya-Wen Sun, Jian Xu, Jun Zhou, Wen-Juan Liu
Brain metastases are very common in lung cancer patients. The condition of these patients is complicated and difficult to treat, and adverse reactions following treatment can affect the nervous system, which severely reduces quality of life. Lung cancers are categorized as small cell lung cancers and non-small cell lung cancers. Patients with brain metastasis of small cell lung cancers are generally treated with brain radiotherapy and systemic chemotherapy, but stage III/IV patients with brain metastasis of non-small cell lung cancers are generally not responsive to radiotherapy or chemotherapy...
January 12, 2018: Oncotarget
https://www.readbyqxmd.com/read/29434454/sequential-spinal-and-intracranial-dural-metastases-in-gastric-adenocarcinoma-a-case-report
#18
Hongsik Kim, Kyung Sik Yi, Won-Dong Kim, Seung-Myoung Son, Yaewon Yang, Jihyun Kwon, Hye Sook Han
Dural metastasis from primary gastric adenocarcinoma has been rarely reported, and its prognosis is very poor because it frequently leads to acute subdural hematoma. Here, we describe a case with sequential spinal and cranial dural metastases from gastric adenocarcinoma without subdural hematoma. A 43-year-old woman with gastric adenocarcinoma and well-controlled peritoneal carcinomatosis presented with back pain, right radiating leg pain, left facial palsy, and hearing loss. Magnetic resonance imaging of the spine and brain revealed dural masses at the lumbosacral junction with invasion to the L5 and S1 nerve roots and at the skull base with invasion to the internal auditory canal...
February 7, 2018: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29433469/combination-of-anti-pd-1-therapy-and-stereotactic-radiosurgery-for-a-gastric-cancer-patient-with-brain-metastasis-a-case-report
#19
Min-Joo Ahn, Kanghan Lee, Kyung Hwa Lee, Jin Woong Kim, In-Young Kim, Woo Kyun Bae
BACKGROUND: Brain metastases from gastric cancer are difficult to treat and their prognosis is poor. Despite various possible treatments, the survival rate of such patients is still unsatisfactory; therefore, new treatment modalities or combinations of therapies need to be explored. CASE PRESENTATION: We herein discuss a case of a 38-year-old man initially diagnosed with a gastric cancer brain metastasis. At first, only stereotactic radiosurgery (SRS) was performed, but it was not effective...
February 12, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29429648/the-usefulness-of-fibrin-glue-as-a-support-in-the-dissection-of-malignant-cystic-brain-tumors
#20
J Todeschi, Y Pin, F Lersy, F Séverac, I Ollivier, S Kremer, F Proust, H Cebula
BACKGROUND: If the complete microsurgical resection of a brain tumor is a logical oncologic goal, the surgical strategy for the cystic component remains controversial secondary to the risk of morbidity. The objective of this study was to analyze the interest of using fibrin glue in the resection of malignant cystic brain tumors (MCBT). METHODS: Seven patients (median: 60-years-old (range [52-72]/sex ratio M/F: 2.5) were analyzed prospectively in the Neurosurgery Department at Strasbourg University Hospital, from October 2014 to November 2016...
February 8, 2018: Neuro-Chirurgie
keyword
keyword
24730
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"